In the original article, there was a mistake in Table 2. Possible Screening for pMODS for Pediatric and Adolescent-Young Adult (AYA) HCT Patients as published.
Table 2
| Score+ | 0 | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| Respiratoryc Oxygen support on the HCT floors PaO2/FiO2 (P/F) ratio SpO2/FiO2 (P/F) ratio | Room air | Blow-by oxygen and ≥400 ≥292 | Nasal Cannula or 300-399 264-291 | NIV or 200-299 221-263 | MV and/or 100-199 with respiratory support 148-220 with respiratory support | MV and/or <100 with respiratory support <148 with respiratory support |
| CV (MAP by age group, mmHg)d < 1 month 1-11 months 12-23 months 24-59 months 60-143 months 144-215 months >216 months or Vasoactive infusion, μg/kg/min | ≥ 46 ≥ 55 ≥ 60 ≥ 62 ≥ 65 ≥ 67 ≥ 70 | < 46 < 55 < 60 < 62 < 65 < 67 < 70 | Dopamine hydrochloride < 5 or dobutamine hydrochloride (any) | Dopamine hydrochloride 5-9.9 or epinephrine < 0.1 or norepinephrine bitartrate ≤ 0.1 | Dopamine hydrochloride 10-14.9 or epinephrine 0.1-0.2 or norepinephrine bitartrate 0.1-0.2 | Dopamine hydrochloride > 15 or epinephrine > 0.2 or norepinephrine bitartrate > 0.2 |
| Renal KDIGO AKI Criteria Patients must have one of the following 1. Increase in baseline Serum creatinine (bSCr) ≥ 0.3 mg/dL within 48 hrs 2. Increase in bSCr ≥ 1.5x baseline that is known or presumed to have occurred within past 7 d 3. Urine volume < 0.5 mL/kg/hr for 6 hr | Baseline (No AKI) | KDIGO 1 1.5-1.9 x bSCr or Cr increase > 0.3 mg/dL or Urine volume < 0.5 mL/kg/hr for 6-12 hours | KDIGO 2 2-2.9 x bSCr or Urine volume < 0.5 mL/kg/hr for >12 hours | KDIGO 3 >3 x bSCr or Cr > 4 mg/dL or Initiation of RRT or Urine volume < 0.5 mL/kg/hr for > 24 hours or Anuria> 12 hours | ||
| Renal Weight gain – after diuretics | Baseline | 2-5% | >5-10% | >10% | Persistent rise >10% | RRT |
| Hepatic Total Bilirubin | Baseline | ≥ 2 | Doubles in 48h | Doubles in 24h | ||
| Hematologic INR or Refractory Thrombocytopenia | <1.2 | 1.2 -1.5 < 3 days | >1.5-1.9 3-7 days | ≥2 | Need replacement of factors > 7 days | Active Bleeding |
| CNS CAPDe | Baseline or <9 | Initial increase from baseline, but < 9 | Sequential increase from baseline, but < 9 | ≥ 9 | Sequential increase > 9 | ≥ 9 and/or recent/active CVA, PRES, or seizures |
| Immune Reconstitutionf ANC ALC Acute GVHD (75) Active infection | >1500/mm3 >1500/mm3 None None | >1000-1500/mm3 >1000-1500/mm3 Stage 1 H/o clinically significant infection | 500-1000/mm3 >800 -1000/mm3 Stage 2 Active controlled | < 500/mm3 500-800/mm3 Stage 3 Active uncontrolled | <200/mm3 <500/mm3 Stage 4 Multiple active/uncontrolled infections | <100/mm3 <200/mm3 Stage 4 Multiple active/uncontrolled infections |
Possible Screening for pMODS for Pediatric and Adolescent-Young Adult (AYA) HCT Patientsab.
a. May be performed weekly and if clinically significant deterioration. Use the worst value in preceding 24-hour period for each variable b. If concern for pMODS, recommend further screening for endotheliopathies such as CLS, ES, TMA, DAH, IPS, and/or SOS. c. P/F ratio to be used when arterial blood gas is available. Otherwise, use S/F ratio. d. MAP = (1/3 x SBP) + (2/3 x DBP) e. CAPD change from baseline should also be taken into consideration when using CAPD score. e. ANC: absolute neutrophil count [white blood cell count (k/uL) x (%neutrophils+ bands) x 10 f. ALC: absolute lymphocyte count [white blood cell count (k/uL) x (% lymphocytes) x 10 + patients receiving end of life care may be delineated with an organ score and “E” (example 4E); this designation is intended to retain awareness of specific goals of care and explicitly state rationale when invasive organ support interventions are not initiated. f. Assign the highest score if any 1 criteria is met in this category.
The following in Table 2 has been corrected:
Respiratory: Score 0 and Score 2; CV: Score 2; Renal: Score 4; Hematologic: Score 0, Score 1, Score 2, and Score 3; CNS: Score 0 and Score 4; Immune Reconstitution: Score 1 and Score 2 and Footnote f.
The corrected Table 2. Possible Screening for pMODS for Pediatric and Adolescent-Young Adult (AYA) HCT Patients appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Reference
75
RowlingsPAPrzepiorkaDKleinJPGaleRPPasswegJRHenslee-DowneyPJet al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 97(4):855–64. doi: 10.1046/j.1365-2141.1997.1112925.x
Summary
Keywords
pediatric stem cell transplantation, pediatric critical care, multiple organ dysfunction, pediatric critical care illness severity scores, pediatric multi-organ dysfunction syndrome
Citation
Ahmad AH and Mahadeo KM (2021) Corrigendum: Perspective: A Framework to Screen Pediatric and Adolescent Hematopoietic Cellular Therapy Patients for Organ Dysfunction: Time for a Multi-Disciplinary and Longitudinal Approach. Front. Oncol. 11:679526. doi: 10.3389/fonc.2021.679526
Received
12 March 2021
Accepted
12 March 2021
Published
23 April 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2021
Updates
Copyright
© 2021 Ahmad and Mahadeo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kris M. Mahadeo, kmmahadeo@mdanderson.org
This article was submitted to Pediatric Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.